The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 8, 2022 | Huang James | Director | Buy(P) | 33K | $4.28 | $143K |
| Sep 7, 2022 | Huang James | Director | Buy(P) | 3K | $4.00 | $12K |
| Sep 7, 2022 | Zukiwski Alexander A | EVP and Chief Medical Officer | Grant(A) | 3K | — | $0 |
| Sep 6, 2022 | Huang James | Director | Buy(P) | 19K | $3.89 | $75K |
| Sep 2, 2022 | Huang James | Director | Buy(P) | 400 | $3.74 | $1K |
| Sep 1, 2022 | Huang James | Director | Buy(P) | 12K | $3.72 | $44K |
| Aug 31, 2022 | Huang James | Director | Buy(P) | 25K | $3.75 | $94K |
| Aug 26, 2022 | Huang James | Director | Buy(P) | 40K | $3.75 | $148K |
| Aug 24, 2022 | Huang James | Director | Buy(P) | 5K | $3.75 | $19K |
| Aug 23, 2022 | Huang James | Director | Buy(P) | 40K | $3.50 | $140K |
| Aug 22, 2022 | Huang James | Director | Buy(P) | 23K | $3.46 | $80K |
| Aug 19, 2022 | Huang James | Director | Buy(P) | 171K | $3.27 | $560K |
| Jun 15, 2022 | He Wei-Wu | Chairman and CEO, Director, 10% Owner | Buy(P) | 50K | $3.18 | $159K |
| Jun 14, 2022 | He Wei-Wu | Chairman and CEO, Director, 10% Owner | Buy(P) | 2K | $3.06 | $6K |
| Jun 13, 2022 | He Wei-Wu | Chairman and CEO, Director, 10% Owner | Buy(P) | 36K | $2.97 | $107K |
| May 25, 2022 | Zhou Quan | Director | Grant(A) | 381K | — | $0 |
| May 25, 2022 | Huang James | Director | Grant(A) | 397K | — | $0 |
| May 25, 2022 | Wu Yue Alexander | Director | Grant(A) | 388K | — | $0 |
| May 25, 2022 | Salisbury Franklin Cary jr | Director | Grant(A) | 388K | — | $0 |
| May 25, 2022 | Shrotriya Rajesh C MD | Director | Grant(A) | 346K | — | $0 |
| Dec 2, 2021 | Zukiwski Alexander A | Chief Medical Officer | Grant(A) | 500K | — | $0 |
| Nov 18, 2021 | He Wei-Wu | Chairman and CEO, Director | Buy(P) | 200K | $0.98 | $196K |
| Nov 17, 2021 | He Wei-Wu | Chairman and CEO, Director | Buy(P) | 200K | $0.99 | $198K |
| Aug 19, 2021 | He Wei-Wu | Chairman and CEO, Director | Buy(P) | 180K | $1.26 | $227K |
| Aug 18, 2021 | He Wei-Wu | Chairman and CEO, Director | Buy(P) | 300K | $1.29 | $387K |
| Jul 24, 2021 | Zhang Larry | President | Grant(A) | 800K | — | $0 |
| Jun 15, 2021 | Zhou Quan | Director | Grant(A) | 108K | — | $0 |
| Jun 15, 2021 | Wu Yue Alexander | Director | Grant(A) | 110K | — | $0 |
| Jun 15, 2021 | Shrotriya Rajesh C MD | Director | Grant(A) | 98 | — | $0 |
| Jun 15, 2021 | Salisbury Franklin Cary jr | Director | Grant(A) | 110K | — | $0 |
| Jun 15, 2021 | Huang James | Director | Grant(A) | 113K | — | $0 |
| Jun 15, 2021 | He Wei-Wu | Chairman and CEO, Director, 10% Owner | Grant(A) | 4.0M | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2021-03-29 → 2026-07-11. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).